10 women’s health innovations selected for Accelerating FemTech: Evaluate

Following a competitive application process, 10 innovations have been selected for Accelerating FemTech: Evaluate.

Share:
Published: 27th November 2025

The Accelerating FemTech: Evaluate cohort Logos for cohort - Belle, Bloume Health, BreathPredict, Dignitycare, Lumino, Matresa, Meyva, Niramai, P.Happi, Upskill Logos for partners: Innovate UK, Health Innovation Network South London. Digital Health London, Accelerating FemTech: Evaluate

The new Accelerator, which was announced in September as part of the Innovate UK Biomedical Catalyst competition, is specifically designed for women’s health solutions with a technology readiness level (TRL) 4 or above to support them enter their chosen market. It is delivered by the Health Innovation Network South London (HIN), DigitalHealth.London and partners from across the UK.

Women spend around 25% more of their lives in ill health compared to men. Despite this, only 1% of global healthcare research and innovation is dedicated to women-specific conditions. Accelerating FemTech: Evaluate is designed to help UK-based businesses to connect with the right people for evidence generation and plan a pathway for evaluation, marking an important step towards driving the spread and adoption of evidence-backed women’s health innovations.

The 10 innovations selected for Accelerating FemTech: Evaluate demonstrate a high potential for addressing real-world women’s healthcare challenges, spanning a diverse range of pathways and systems. These novel technologies and personal products include a heated bra designed for hormonal breast tenderness; cognitive behavioural therapy (CBT) for menopause support; biosensors to help detect respiratory diseases; compassionate support for women experiencing pregnancy loss; and a pioneering AI-powered thermal imaging tool for breast health screening.

Lived experience directly informs many of the solutions, such as a microbiome serum born from a founder’s experience of recurrent urinary tract infections; and a training platform for maternity staff, which brings to life the experiences of local women through VR.

The cohort also sees solutions that support the move to healthcare in the community, including a digital preventive maternal health platform; a therapeutic platform to improve quality of life for people living with Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Syndrome (PMS); and an agency-building app for people living with chronic pelvic pain.

Over three months, these innovations will be helped through a hybrid curriculum, including virtual training and face-to-face support from a business coach, who will help with identifying strategic collaborations and real-world evaluation routes, such as health economic analyses. Companies will also benefit from two residentials (onboarding and
mid-programme), a series of webinars lead by subject matter experts, one-to-one sessions with mentors across the health and care system, and an end of programme showcase, as well as the opportunity to apply for the special closed call feasibility funding through the Innovate UK Biomedical Catalyst.

Now more than ever, it is crucial that innovations are routed in evaluative principles and provide real value for patients, as well as the wider healthcare system. This is particularly important in women’s health, which faces additional historic barriers, such as the gender data gap.

We need more innovation and access to better care in women’s health—and with limited funding flowing into the sector, programmes like this are so vital. We’re thrilled to have the opportunity to join the Accelerating FemTech: Evaluate programme alongside other changemakers. P.Happi, born from science and personal experience, will use this opportunity to advance our mission of making pioneering microbiome innovation accessible to more women through community and public healthcare. With the support of the HIN and Innovate UK, we’re truly excited to get started.

Dr Chiara Board, CEO and Founder of P.Happi

I’m really proud that Meyva has been selected for the Accelerating FemTech: Evaluate programme. This opportunity will help us build the evidence needed to support heat therapy as a safe, effective option for women experiencing cyclical mastalgia. For too long, breast pain has been dismissed or overlooked. It means a lot to see this issue recognised and to be part of a programme helping women’s health innovations move from personal experience to real-world impact.

Anja Ueland, Director of Meyva

We are honoured to be selected for the Accelerating FemTech: Evaluate programme. This recognition reinforces our mission to make advanced, accessible health screening available to women everywhere. Through this initiative, we look forward to collaborating with the UK’s vibrant health innovation ecosystem to expand Niramai’s clinically proven, AI-based Thermalytix® technology, improve early breast cancer detection, and contribute to the NHS’s goals for equitable and preventive women’s health.

Geetha Manjunath, CEO of Niramai Health Analytix

Accelerating FemTech: Evaluate is a 10-week Innovate UK Biomedical Catalyst Accelerator that supports UK companies with technologies for women’s health that are already developed but are looking to prove their value. Funded by Innovate UK Biomedical Catalyst and delivered by the Health Innovation Network South London with national partners, it offers tailored support, expert workshops and one-to-one business coaching. The goal is to help companies grow, connect with the right people and plan testing of solutions in real-world healthcare settings, including cost-effectiveness. The programme builds on the HIN’s strong track record of convening national partners to drive the growth of innovation in women’s health. Between September 2023 and March 2025, their early-stage accelerator supported 33 pioneering solutions to build the commercial and funding momentum needed for long-term success. The two cohorts went on to secure over £1million in a special closed-call feasibility funding opportunity through Innovate UK Biomedical Catalyst.

The Health Innovation Network South London is the health innovation network for south London, one of 15 across England. We are an NHS team that works flexibly to connect the health and care sector, academia, local authorities and industry to speed up innovation and improve care, in partnership with south London residents. Since 2013, we have helped change services and health outcomes for the better. We advise and connect innovators with the NHS in regional, national and international projects, supporting the spread of innovation through pilots and evaluation.

Accelerating FemTech: Evaluate is delivered in partnership with national partners, including:

DigitalHealth.London; CW+; Royal College of Obstetricians and Gynaecologists; Health Innovation East; Health Innovation East Midlands; Health Innovation Kent, Surrey and Sussex; Health Innovation North East and North Cumbria; Health Innovation North West Coast; Health Innovation Oxford and Thames Valley; Health Innovation Wessex; Health Innovation West of England; Health Innovation Yorkshire and Humber; Digital Health and Care Innovation Centre; Health Innovation Research Alliance Northern Ireland; Mills & Reeve; Modality Partnership; Chelsea and Westminster Hospital NHS Foundation Trust; Gateshead Health NHS Foundation Trust; Liverpool University NHS Foundation Trust; and St George’s University Hospitals NHS Foundation Trust.

You might also like…

image of a woman holding a tube shaped product on a yellow background
Life after breast cancer: a focus on positive intimate health

For Breast Cancer Awareness Month, Dr. Chiara Board, founder of P.Happi®, shares two patient stories which illustrate her motivation to address one of the common side effects women experience after breast cancer treatment – an issue that P.Happi® aims to address across women’s health more broadly.

Read more

Share your idea

Do you have a great idea that could deliver meaningful change in the real world?

Get involved

Newsletter